 Iovance Biotherapeutics Inc NASDAQ: IOVA has announced data for lifileucel in combination with Merck Co Incs NYSE: MRK Keytruda pembrolizumab in patients with advanced cancers. Data were presented at the Society for Immunotherapy of Cancer Annual Meeting. 